20 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
11266171	4	RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.	Aventis Pharma
28280261	84	Non-kinase targets of protein kinase inhibitors.	The University of Sydney
22901390	44	Synthesis and biological activity of pyridopyridazin-6-one p38a MAP kinase inhibitors. Part 2.	Merck Research Laboratories
18039577	62	Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.	Eli Lilly
15177483	33	SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.	Novartis Institutes For Biomedical Research
20378346	25	Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.	Merck Research Laboratories
16249085	26	Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.	Novartis Institutes For Biomedical Research
15177482	90	Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.	Novartis Institutes For Biomedical Research
14698158	13	A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.	Novartis Institute For Biomedical Research
12565927	24	Imidazopyrimidines, potent inhibitors of p38 MAP kinase.	Johnson & Johnson Pharmaceutical Research and Development
12540232	53	Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.	Merck Research Laboratories
12127515	29	SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.	Novartis Pharma
32543856	3	Mining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein-Protein Inhibitors: Two Test Cases Illustrated by IL1?-IL1R and p38?-TAB1 Complexes.	King'S College London
10866395	33	SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.	Novartis Pharma